{"name":"BIND Therapeutics","slug":"bind-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":15401000,"revenueGrowth":140,"grossMargin":0,"rdSpend":37273000,"netIncome":-36579000,"cash":50742000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BIND-014","genericName":"BIND-014","slug":"bind-014","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"BIND-014","genericName":"BIND-014","slug":"bind-014","phase":"phase_2","mechanism":"BIND-014 is a targeted delivery system for small interfering RNA (siRNA) that targets the PD-1/PD-L1 pathway.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPeTFDT1RyRUhCVS1RaUtEMTZQUEM5bVVYcUZTdjk4NnVXdFlrMjJGMXJvQUVlZWY3QmFBSnMxMndtMk16dS1wcFVYV1FLMnF4QlB5RENCNGdtR0h3UG9ldXFOV1Q2ajd2Mm5uLWRwV0Mxai1CUU1FdVBtdHRPYmh6WC1aSEhwUmlSYmx4Q2ZYSnhwYVAxR0lEbE9zWDRzUXdaRzI4Nm9kMGJTUmFxRG5CNzJDaw?oc=5","date":"2026-03-02","type":"deal","source":"Stock Titan","summary":"AI-designed lung cancer drug deal puts Kairos in $16.2B market - Stock Titan","headline":"AI-designed lung cancer drug deal puts Kairos in $16.2B market","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-02","type":"pipeline","source":"TradingView","summary":"Kairos Pharma Announces Signing Of Binding Strategic Asset Acquisition Of Exclusive Worldwide Rights To Cl-273 From Orbimed And Torrey Pines Investment-Backed Celyn Therapeutics - TradingView","headline":"Kairos Pharma Announces Signing Of Binding Strategic Asset Acquisition Of Exclusive Worldwide Rights To Cl-273 From Orbi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE0zemxSS1lRQ0NsMVpJelc4eUNlMjg2cVQ4dXZEUF9jMVlldTl6bURtaUFyNFBzbmVfbFFmYnVnVmJWMHJtMmY3T3JQYVJJY2d5UnJr?oc=5","date":"2026-02-12","type":"pipeline","source":"FirstWord Pharma","summary":"Terray touts benchmark-beating accuracy and speed of AI potency prediction model - FirstWord Pharma","headline":"Terray touts benchmark-beating accuracy and speed of AI potency prediction model","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-20","type":"pipeline","source":"The Economic Times","summary":"Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever - The Economic Times","headline":"Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxObVZ3XzVzRjFyVUs4ZE9PWkxvbF9lcWdoWnpSbG1rVmF3QWtzVVpzVzY0VXlkeXR3R2hYaFJ6czBIWVcwZ29hVUFReFJodDg4MkNOYkZaeWdIXzJGZmZTNC1Sa0VHbzA5VklKS1RtNnZUang3LS1DQjRUNWJXd0IzZ0ZQQW0wTGNlRmp4VkJPSWdobkU?oc=5","date":"2025-06-17","type":"trial","source":"Yahoo Finance","summary":"Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate - Yahoo Finance","headline":"Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPMGVRV3FmakVRUGFUWUdvTkI3OEZKMVllZkFTWE1VTEkyd2pmVmFSYmdKRHZjZmxwV01IQ0xMTDFxR3pPTV95emRoZE9Zb2t1cC1zYTJuT0p1Nm5ub1BfUmdtcTFzYlJqYUZyWllpZDdHZ0RWMVR6MUhKTkRrQmxzU3QwcUdFY3pfM1RfNlVRYzFUckZ5ZFhWdzdhcGdDaXplQ2xxR0NQNlJfdDZxeG54UHJQbmg3eHhyNlFYVQ?oc=5","date":"2025-06-17","type":"trial","source":"Stock Titan","summary":"$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest - Stock Titan","headline":"$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNZFdOMERVX1FLckppdVVJWHJjM09vNjJxTmtQX21nbkNOeVc2b0xYcnRyb0ZXNF9FckZ1OExNOEtxWlhYS2dGNUVyMzJBWkVucUNKZjVINHpNaU0tZmhYREU5QTU1LW1RclcxQlB5elVjeG9BUi15NHF1R1FabEI1YmZFYmJweG1MeGtzX1Y2b3F2aVFxcS1NSnlRNG9uLUs2ejJQYzBtd1hEaUFmWFplVDNNUWVJQmNGSVhRUDQwWmdEeEJJdXl3ZmdtVQ?oc=5","date":"2024-12-23","type":"pipeline","source":"PR Newswire","summary":"NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS - PR Newswire","headline":"NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQOU81LUcycmdFRlNGREE4NGctS3k2dUZtM2xXcEhuSlpVNG1pMkRBMUgxaWloZkZZWE5qc2Fxd2lpZHBhUTdSSzNreE5JbVJxeV9ieURXc2pEVXFGbDUyeEx5RGplQ3NvYjlONWZXenJXcjFqWFY3S2dxbUFrRDFRbFQ4RklpY2FPcXI0TTQ4T21XWXY3bFNZSTVqMXdHa09wNEMxMGhzTDJra1VISUgyWFNXY3g?oc=5","date":"2020-09-09","type":"pipeline","source":"Fierce Biotech","summary":"After Bind bankruptcy, Hirsch once again helms a biotech, landing at C4 - Fierce Biotech","headline":"After Bind bankruptcy, Hirsch once again helms a biotech, landing at C4","sentiment":"neutral"},{"date":"2019-11-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2018-04-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2018-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2017-09-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE5ma3A0TEVlaEZ5aW9SdWRPd29HcXVrZFh4c0U4dVFDOTVEX3lNaVR1dG9vdEE4UU5URVVOaGNNeHpmMEpLbWZMSEI3azgyek9zaFR6b3FPeHdkdV82VTcwbTIxRFlIV2VCOEh3WmQ5aVJpUQ?oc=5","date":"2017-08-01","type":"pipeline","source":"Nanalyze","summary":"WTF Happened to Bind Therapeutics? - Nanalyze","headline":"WTF Happened to Bind Therapeutics?","sentiment":"neutral"},{"date":"2017-04-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2017-02-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":15401000,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":15401000,"period":"2015-12-31"},{"value":6417000,"period":"2015-12-31"},{"value":2076000,"period":"2015-09-30"},{"value":2524000,"period":"2015-06-30"},{"value":4384000,"period":"2015-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":37273000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-36579000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":50742000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}